Abeona Therapeutics (ABEO) stock price is $4.47, down 0.89% on the day, as of Oct 22, 2026. It has a market cap of $247.48Mn, and is classified in the Gene and Cell Therapy industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap247.48 Mn
P/E-3.87
P/S9.70
Div. Yield0.00
Total Debt (Qtr)14.99 Mn
Revenue Growth (1y) (Qtr)2,745.00
Add ratio to table…
About
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The company’s lead approved product is ZEVASKYN, an autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. ZEVASKYN is manufactured at the company’s current Good Manufacturing Practices facility in Cleveland Ohio and is administered through a…
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. The company’s lead approved product is ZEVASKYN, an autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. ZEVASKYN is manufactured at the company’s current Good Manufacturing Practices facility in Cleveland Ohio and is administered through a network of qualified treatment centers. In addition to its commercial product Abeona maintains a research and development pipeline focused on adeno-associated virus based gene therapies that utilize the company’s AIM™ capsid platform to target ophthalmic conditions such as X-linked retinoschisis Stargardt disease and autosomal dominant optic atrophy. The company partners with academic institutions patient advocacy groups and other biotechnology firms to advance its programs and seeks to protect its innovations through a robust intellectual property portfolio.
Abeona Therapeutics Inc. generates revenue primarily from the sale of ZEVASKYN to qualified treatment centers that administer the therapy to eligible patients. The company also receives income from licensing agreements that provide upfront payments milestone payments and royalties on net sales of products that incorporate its AIM™ capsid technology or other proprietary assets. Notable licensing arrangements include a non-exclusive agreement with Beacon Therapeutics for the AAV204 capsid and out-licenses to Ultragenyx Pharmaceutical Inc. and Taysha Gene Therapies Inc. for specific gene therapy programs. In addition Abeona realized a one-time proceeds from the sale of a Priority Review Voucher awarded upon ZEVASKYN’s approval. Revenue is further supported by broad insurance coverage including Medicare Medicaid and private insurers that reimburse for the administration of ZEVASKYN at certified centers.
Abeona Therapeutics Inc. occupies a distinctive position in the cell and gene therapy sector as the developer of the first and only FDA-approved autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa. The product benefits from orphan drug designation which provides a period of market exclusivity and regulatory incentives that reduce competitive pressure. While other companies such as Krystal Biotech with its topical gene therapy Vyjuvek and traditional gene therapy firms like Spark Therapeutics and Regenxbio pursue overlapping therapeutic areas Abeona differentiates itself through its integrated manufacturing capabilities its proprietary AIM™ capsid library and its extensive patent estate covering vector design manufacturing processes and clinical applications. These assets enable the company to control supply chain quality and to pursue multiple therapeutic indications simultaneously.
The company’s customer base consists of patients with recessive dystrophic epidermolysis bullosa who receive ZEVASKYN through a network of qualified treatment centers. As of March 2026 Abeona had activated four centers including Ann & Robert H. Lurie Children’s Hospital of Chicago Lucile Packard Children’s Hospital Stanford Children’s Hospital Colorado and the University of Texas Medical Branch in Galveston Texas. These centers are selected for their expertise in cell and gene therapy and have undergone specific training to administer the therapy. In addition to patient customers Abeona serves licensing partners such as Beacon Therapeutics Ultragenyx and Taysha which pay fees and royalties for the use of its proprietary technologies. Reimbursement for ZEVASKYN is obtained from governmental payers including the Centers for Medicare and Medicaid Services and Medicaid programs across all fifty states and Puerto Rico as well as from numerous national and regional commercial health insurers.
Sector:HealthcareSector rationaleAbeona Therapeutics is a biopharmaceutical company that develops and sells cell and gene therapies, specifically ZEVASKYN for recessive dystrophic epidermolysis bullosa. Its revenue is derived from the sale of these medical treatments to treatment centers and licensing its proprietary AIM™ capsid technology to other biotechnology firms.Industry:Gene and Cell TherapyGene and Cell TherapyPrimaryAbeona Therapeutics develops and commercializes cell and gene therapies, specifically its lead approved product ZEVASKYN, an autologous cell-based gene therapy. The company also maintains a pipeline of adeno-associated virus (AAV) based gene therapies using its proprietary AIM™ capsid platform.Classified using BQ-MICSCIK: 0000318306
Bull & bear
Investment Thesis
▲ Bull case
Abeona Therapeutics is positioned for accelerating commercial traction in ZEVASKYN due to expanding qualified treatment center coverage and a large identified patient pool, with management indicating that each activated QTC can sustain a cadence of approximately one patient treatment per month at steady state, which, when scaled to the targeted 10 centers by end of 2026, could support over 100 annual treatments and significantly exceed current quarterly run rates, especially as onboarding bottlenecks ease and geographic barriers prove non-limiting based on patient willingness to travel across state lines for therapy.
The company’s pricing power and gross-to-net trajectory are improving meaningfully, as evidenced by the shift from Medicaid to commercial payer mix in Q1 2026 reducing rebate exposure from 23.1% to mid-to-upper teens, a trend expected to strengthen with 60% commercial and 30%-33% Medicaid split in near-term treatments, directly enhancing revenue per patient and contributing to the CFO’s projection of monthly operating profitability potentially as early as June 2026, supported by a still-robust cash balance of $168.3 million despite quarterly burn.
The in-licensing of PSMA-SIR-T represents a strategic pivot with limited near-term financial burden, as R&D spend for the program is expected to remain in the low single-digit millions for the remainder of 2026, allowing Abeona to advance a differentiated oncology asset with potential to overcome historical solid tumor limitations of CAR-T therapies without diverting critical resources from ZEVASKYN commercialization, while leveraging existing CMC expertise and prior commercial team experience in hematologic CAR-T launches to de-risk development.
Clinical durability data for ZEVASKYN, including 5-year follow-up from the VIITAL Phase III trial and a single-patient 12-year data point from Phase I/IIa, reinforces long-term efficacy and safety after a one-time application, which, when combined with positive qualitative feedback from treated patients and caregivers, strengthens the therapy’s value proposition and supports patient self-referral dynamics through the Strong Together Network, creating a organic demand engine that could reduce reliance on physician outreach over time.
Management’s disciplined capital allocation is evident in the deprioritization of non-core ophthalmology preclinical programs and the decision to externalize PSMA-SIR-T manufacturing to a CDMO, preserving internal operational focus on ZEVASKYN scale-up while minimizing near-term cost inflection, a strategy that aligns with achieving scalable, profitable growth in the core rare disease franchise before pursuing broader pipeline expansion.
Abeona Therapeutics is positioned for accelerating commercial traction in ZEVASKYN due to expanding qualified treatment center coverage and a large identified patient pool, with management indicating that each activated QTC can sustain a cadence of approximately one patient treatment per month at steady state, which, when scaled to the targeted 10 centers by end of 2026, could support over 100 annual treatments and significantly exceed current quarterly run rates, especially as onboarding bottlenecks ease and geographic barriers prove non-limiting based on patient willingness to travel across state lines for therapy.
The company’s pricing power and gross-to-net trajectory are improving meaningfully, as evidenced by the shift from Medicaid to commercial payer mix in Q1 2026 reducing rebate exposure from 23.1% to mid-to-upper teens, a trend expected to strengthen with 60% commercial and 30%-33% Medicaid split in near-term treatments, directly enhancing revenue per patient and contributing to the CFO’s projection of monthly operating profitability potentially as early as June 2026, supported by a still-robust cash balance of $168.3 million despite quarterly burn.
The in-licensing of PSMA-SIR-T represents a strategic pivot with limited near-term financial burden, as R&D spend for the program is expected to remain in the low single-digit millions for the remainder of 2026, allowing Abeona to advance a differentiated oncology asset with potential to overcome historical solid tumor limitations of CAR-T therapies without diverting critical resources from ZEVASKYN commercialization, while leveraging existing CMC expertise and prior commercial team experience in hematologic CAR-T launches to de-risk development.
Clinical durability data for ZEVASKYN, including 5-year follow-up from the VIITAL Phase III trial and a single-patient 12-year data point from Phase I/IIa, reinforces long-term efficacy and safety after a one-time application, which, when combined with positive qualitative feedback from treated patients and caregivers, strengthens the therapy’s value proposition and supports patient self-referral dynamics through the Strong Together Network, creating a organic demand engine that could reduce reliance on physician outreach over time.
Management’s disciplined capital allocation is evident in the deprioritization of non-core ophthalmology preclinical programs and the decision to externalize PSMA-SIR-T manufacturing to a CDMO, preserving internal operational focus on ZEVASKYN scale-up while minimizing near-term cost inflection, a strategy that aligns with achieving scalable, profitable growth in the core rare disease franchise before pursuing broader pipeline expansion.
Abeona Therapeutics faces persistent commercial execution risks due to lengthy and variable qualified treatment center onboarding timelines, with CMC and clinical training processes sometimes exceeding a year, which constrains near-term treatment capacity expansion despite an identified patient pool exceeding 100, and management’s own admission that predicting biopsy-to-treatment conversion is highly uncertain due to borderline cases and imprecise manufacturing turnaround times (23–26 days), creating revenue recognition volatility that could disrupt quarterly forecasts.
The path to profitability remains fragile and contingent on volatile patient treatment cadence, as the CFO’s projection of monthly operating profitability starting potentially in June 2026 relies on assumptions about biopsy scheduling and payer approval timelines that are inherently unpredictable, particularly for out-of-state Medicaid patients navigating layered enrollment requirements, and any delay in QTC activation or patient throughput could quickly erode the cash position, which declined by $23.1 million from $191.4 million at end-2025 to $168.3 million in Q1 2026 despite only one quarter of meaningful commercial revenue.
While gross-to-net metrics improved in Q1 2026 due to a commercial-payer-heavy mix, the long-term sustainability of favorable pricing is uncertain given the expected near-term treatment split of 60% commercial and 30%-33% Medicaid, which will reintroduce meaningful rebate exposure (historically 23.1% for Medicaid) and pressure net revenue per patient, especially if commercial payer penetration does not continue to increase beyond current levels as volume scales.
The PSMA-SIR-T in-licensing, while strategically compelling, introduces future clinical and regulatory risks unrelated to Abeona’s core competencies, with IND filing not targeted until second half of 2027 and first-in-human data years away, meaning the $7 million upfront payment may not yield tangible near-term value and could instead distract leadership focus during a critical phase of ZEVASKYN commercialization, particularly if preclinical promise does not translate to human efficacy in solid tumors where prior engineered T-cell therapies have failed.
Manufacturing and logistical complexities remain underappreciated risks, as the company’s current turnaround time from biopsy to delivery (23–26 days) leaves minimal buffer for delays in shipping, cold chain maintenance, or manufacturing yield variability, and any disruption in this tight window could compromise product availability and patient trust, especially as Abeona explores international expansion where logistical challenges from its Cleveland site are anticipated to be significant, yet no concrete mitigation plan has been detailed for near-term execution.
Abeona Therapeutics faces persistent commercial execution risks due to lengthy and variable qualified treatment center onboarding timelines, with CMC and clinical training processes sometimes exceeding a year, which constrains near-term treatment capacity expansion despite an identified patient pool exceeding 100, and management’s own admission that predicting biopsy-to-treatment conversion is highly uncertain due to borderline cases and imprecise manufacturing turnaround times (23–26 days), creating revenue recognition volatility that could disrupt quarterly forecasts.
The path to profitability remains fragile and contingent on volatile patient treatment cadence, as the CFO’s projection of monthly operating profitability starting potentially in June 2026 relies on assumptions about biopsy scheduling and payer approval timelines that are inherently unpredictable, particularly for out-of-state Medicaid patients navigating layered enrollment requirements, and any delay in QTC activation or patient throughput could quickly erode the cash position, which declined by $23.1 million from $191.4 million at end-2025 to $168.3 million in Q1 2026 despite only one quarter of meaningful commercial revenue.
While gross-to-net metrics improved in Q1 2026 due to a commercial-payer-heavy mix, the long-term sustainability of favorable pricing is uncertain given the expected near-term treatment split of 60% commercial and 30%-33% Medicaid, which will reintroduce meaningful rebate exposure (historically 23.1% for Medicaid) and pressure net revenue per patient, especially if commercial payer penetration does not continue to increase beyond current levels as volume scales.
The PSMA-SIR-T in-licensing, while strategically compelling, introduces future clinical and regulatory risks unrelated to Abeona’s core competencies, with IND filing not targeted until second half of 2027 and first-in-human data years away, meaning the $7 million upfront payment may not yield tangible near-term value and could instead distract leadership focus during a critical phase of ZEVASKYN commercialization, particularly if preclinical promise does not translate to human efficacy in solid tumors where prior engineered T-cell therapies have failed.
Manufacturing and logistical complexities remain underappreciated risks, as the company’s current turnaround time from biopsy to delivery (23–26 days) leaves minimal buffer for delays in shipping, cold chain maintenance, or manufacturing yield variability, and any disruption in this tight window could compromise product availability and patient trust, especially as Abeona explores international expansion where logistical challenges from its Cleveland site are anticipated to be significant, yet no concrete mitigation plan has been detailed for near-term execution.